Novo Nordisk semaglutide reduced proteomic clock age by up to 4 years in heart tissue across 10,052-patient cohort

Novo Nordisk measured proteomic clocks on blood samples from 10,052 participants in placebo-controlled trials, half receiving semaglutide. Heart-protein clocks showed the largest shift at 4 years; kidney and liver clocks moved 1.5-2.5 years. Eli Lilly recorded comparable tirzepatide effects on its internal cohorts. These readouts align with documented reductions in all-cause mortality and cardiovascular events from the SELECT trial published in NEJM 2023.

Horvath clocks and newer proteomic versions have lacked intervention data until now. The observed shifts occurred alongside weight loss, blood-pressure drops, and improved kidney function, yet the magnitude exceeded what weight reduction alone predicts in prior observational sets. Gladyshev noted the effect size in diseased populations but flagged absence of data in healthy cohorts. Access disparities will determine whether any lifespan extension concentrates in insured populations already screened for metabolic disease.

Operationally, payers and regulators will require clock changes to predict hard endpoints before labeling shifts. Novo plans additional proteomic sampling in ongoing cardiovascular-outcome extensions. Ethical allocation questions intensify if geroprotective claims hold, because current supply constraints and pricing already limit reach to higher-income groups with diagnosed obesity or diabetes.